TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of GBP 3.83 billion. The enterprise value is 3.81 billion.

Market Cap	3.83B
Enterprise Value	3.81B

Important Dates

The next estimated earnings date is Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	145.23M
Shares Outstanding	n/a
Shares Change (YoY)	+9.66%
Shares Change (QoQ)	+1.58%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	135.08M

Valuation Ratios

The trailing PE ratio is 126.36 and the forward PE ratio is 25.06.

PE Ratio	126.36
Forward PE	25.06
PS Ratio	12.80
PB Ratio	20.85
P/TBV Ratio	20.85
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 83.32, with an EV/FCF ratio of -80.63.

EV / Earnings	125.83
EV / Sales	13.38
EV / EBITDA	83.32
EV / EBIT	86.45
EV / FCF	-80.63

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.

Current Ratio	4.02
Quick Ratio	2.91
Debt / Equity	1.07
Debt / EBITDA	4.10
Debt / FCF	-4.17
Interest Coverage	2.10

Financial Efficiency

Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.

Return on Equity (ROE)	19.70%
Return on Assets (ROA)	7.26%
Return on Invested Capital (ROIC)	9.79%
Return on Capital Employed (ROCE)	12.05%
Revenue Per Employee	849,599
Profits Per Employee	86,084
Employee Count	338
Asset Turnover	0.75
Inventory Turnover	0.41

Taxes

In the past 12 months, TG Therapeutics has paid 2.00 million in taxes.

Income Tax	2.00M
Effective Tax Rate	6.21%

Stock Price Statistics

The stock price has increased by +138.40% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+138.40%
50-Day Moving Average	32.07
200-Day Moving Average	23.65
Relative Strength Index (RSI)	66.40
Average Volume (20 Days)	3,606

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.18

Income Statement

In the last 12 months, TG Therapeutics had revenue of GBP 299.06 million and earned 30.30 million in profits. Earnings per share was 0.18.

Revenue	299.06M
Gross Profit	261.45M
Operating Income	46.30M
Pretax Income	32.31M
Net Income	30.30M
EBITDA	46.34M
EBIT	46.30M
Earnings Per Share (EPS)	0.18

Full Income Statement

Balance Sheet

The company has 213.81 million in cash and 197.04 million in debt, giving a net cash position of 16.76 million.

Cash & Cash Equivalents	213.81M
Total Debt	197.04M
Net Cash	16.76M
Net Cash Per Share	n/a
Equity (Book Value)	183.66M
Book Value Per Share	1.26
Working Capital	374.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -47.23 million and capital expenditures -54,179, giving a free cash flow of -47.29 million.

Operating Cash Flow	-47.23M
Capital Expenditures	-54,179
Free Cash Flow	-47.29M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.

Gross Margin	87.43%
Operating Margin	15.48%
Pretax Margin	10.80%
Profit Margin	10.13%
EBITDA Margin	15.49%
EBIT Margin	15.48%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.66%
Shareholder Yield	n/a
Earnings Yield	0.79%
FCF Yield	-1.24%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 3.66 and a Piotroski F-Score of 3.

Altman Z-Score	3.66
Piotroski F-Score	3